ReviewCurrent opinion in rheumatology2016
Biomarkers to guide clinical therapeutics in rheumatology?
Review in Current opinion in rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Proteomic Identification of Plasma Biomarkers of Response to IL-5 Inhibitor Biologics in Healthy Subjects.Clinical and translational science · 2025Trial
- Axial spondyloarthritis, psoriatic arthritis and systemic lupus erythematosus share common molecular features based on post-hoc analysis of serum biomarkers.Rheumatology international · 2025Trial
- Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.Arthritis research & therapy · 2020Trial
- Plasma proteome analysis of rheumatic patients reveals differences in fingerprints based on cardiovascular history: a pilot study.Proteome science · 2025Article
- Profiling joint tissues at single-cell resolution: advances and insights.Nature reviews. Rheumatology · 2024Review
- The Role of Marine n-3 Polyunsaturated Fatty Acids in Inflammatory-Based Disease: The Case of Rheumatoid Arthritis.Marine drugs · 2023Review
- Precision medicine in rheumatoid arthritis.Best practice & research. Clinical rheumatology · 2022Review
- Expectations and educational needs of rheumatologists, rheumatology fellows and patients in the field of precision medicine in Canada, a quantitative cross-sectional and descriptive study.BMC rheumatology · 2021Article
- Metabolomics as a potential tool for the diagnosis of growth hormone deficiency (GHD): a review.Archives of endocrinology and metabolism · 2021Review
- Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential.BMC rheumatology · 2021Article
- Molecular photoacoustic imaging for early diagnosis and treatment monitoring of rheumatoid arthritis in a mouse model.American journal of translational research · 2021Article
- Review
- Immune monitoring using mass cytometry and related high-dimensional imaging approaches.Nature reviews. Rheumatology · 2020Review
- Identification of a HumanFrontiers in immunology · 2020Article
- IgE-mediated mast cell activation promotes inflammation and cartilage destruction in osteoarthritis.eLife · 2019Article
- An Overview of VPAC Receptors in Rheumatoid Arthritis: Biological Role and Clinical Significance.Frontiers in endocrinology · 2019Review
- A Simulation Study Comparing Different Statistical Approaches for the Identification of Predictive Biomarkers.Computational and mathematical methods in medicine · 2019Article
- Biomarkers in Inflammatory Bowel Disease-Associated Spondyloarthritis: State of the Art and Unmet Needs.Journal of immunology research · 2019Review
- Liquid biopsies to guide therapeutic decisions in rheumatoid arthritis.Translational research : the journal of laboratory and clinical medicine · 2018Review
- Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseases: From Mechanistic Insights to Biomarkers.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purpose of reviewThe use of biomarkers in rheumatology can help identify disease risk, improve diagnosis and prognosis, target therapy, assess response to treatment, and further our understanding of the underlying pathogenesis of disease. Here, we discuss the recent advances in biomarkers for rheumatic disorders, existing impediments to progress in this field, and the potential of biomarkers to enable precision medicine and thereby transform rheumatology. RECENT
findingsAlthough significant challenges remain, progress continues to be made in biomarker discovery and development for rheumatic diseases. The use of next-generation technologies, including large-scale sequencing, proteomic technologies, metabolomic technologies, mass cytometry, and other single-cell analysis and multianalyte analysis technologies, has yielded a slew of new candidate biomarkers. Nevertheless, these biomarkers still require rigorous validation and have yet to make their way into clinical practice and therapeutic development. This review focuses on advances in the biomarker field in the last 12 months as well as the challenges that remain. SUMMARY: Better biomarkers, ideally mechanistic ones, are needed to guide clinical decision making in rheumatology. Although the use of next-generation techniques for biomarker discovery is making headway, it is imperative that the roadblocks in our search for new biomarkers are overcome to enable identification of biomarkers with greater diagnostic and predictive utility. Identification of biomarkers with robust diagnostic and predictive utility would enable precision medicine in rheumatology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.